Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma

• Published in: Bone marrow transplantation (Basingstoke) 2024-05, Vol.59 (5), p.647-652
• Main Authors: Mohan, Meera, Szabo, Aniko, Patwari, Anannya, Esselmann, Jean, Patel, Tanvi, Bachu, Ramya, Rein, Lisa E., Janardan, Abhishek, Bhatlapenumarthi, Vineel, Annyapu, Evanka, Skoog, Catherine, Goff, Areyl, Hadidi, Samer Al, Radhakrishnan, Sabarinath Venniyil, Thanendrarajan, Sharmilan, Zangari, Maurizio, Shah, Nirav, van Rhee, Frits, Dhakal, Binod, Hamadani, Mehdi, D’Souza, Anita, Schinke, Carolina
• Format: Article
• Language: English
• Subjects: 692/699/1541/1990/804; 692/700/565/251; Anemia; Cell Biology; Cell therapy; Chimeric antigen receptors; Hematology; Hemoglobin; Internal Medicine; Leukocytes (neutrophilic); Lymphocytes T; Medicine; Medicine & Public Health; Multiple myeloma; Platelets; Public Health; Risk factors; Stem Cells; Therapy; Thrombocytopenia
• ISSN: 0268-3369; 1476-5365; 1476-5365
• DOI: 10.1038/s41409-024-02233-2

Persistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed multiple myeloma (MM). The use of stem cell boosts in ICAHT has been described, however studies have been limited by small patient numbers and short follow up. Herein, we report on our multi-institutional experience of ICAHT, defined by an absolute neutrophil count (ANC) of ≤ 1000, thrombocytopenia with a platelet count ≤ 50,000 or/and anemia as hemoglobin (hgb) ≤9 g/dL, in patients who received BCMA CAR T therapy, and the effects of subsequent stem cell boost on hematopoietic reconstitution and clinical outcome. In this study, ICAHT was observed in 60% ( n  = 61/101) of patients at D + 21, and risk factors for its development included history of a prior ASCT, higher number of prior lines of therapy, a decreased platelet count prior to lymphodepletion and history of ICANS. 28% of patients with ICAHT received a stem cell boost at a median of 116 days due to profound and prolonged cytopenias often requiring ongoing transfusion support. Stem cell boost significantly improved cytopenias at 3 and 6 months follow up without any adverse effects on PFS and OS, underscoring the safety of this procedure.